Oral suspension of temozolomide
US11730732B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 13, 2019 |
| Grant date | Aug 22, 2023 |
| Priority date | — |
| Expiry date | May 1, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.